| Identification | Back Directory | [Name]
LOXO-292 | [CAS]
2222755-14-6 | [Synonyms]
LOX0292
RET-IN-1
Pyrazolo[1,5-a]pyridine-3-carbonitrile, 4-[5-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-2-pyrazinyl]-6-[(2R)-2-morpholinylmethoxy]- | [Molecular Formula]
C29H31N9O3 | [MDL Number]
MFCD32062760 | [MOL File]
2222755-14-6.mol | [Molecular Weight]
553.61 |
| Chemical Properties | Back Directory | [density ]
1.49±0.1 g/cm3(Predicted) | [storage temp. ]
Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). | [solubility ]
Soluble in DMSO | [form ]
solid | [pka]
8.23±0.40(Predicted) | [InChIKey]
GTQISTQEBXXLPC-UBVWURDFSA-N | [SMILES]
C12=C(C#N)C=NN1C=C(OC[C@@H]1OCCNC1)C=C2C1=NC=C(N2CC3CC(N3CC3=CC=C(OC)N=C3)C2)N=C1 |
| Questions And Answer | Back Directory | [Uses]
Serpatinib (LOXO-292) is a potent, orally administered, highly selective transfection rearrangement (RET) kinase inhibitor used to treat cancer patients with RET abnormalities. The RET gene is a proto-oncogene that undergoes rearrangement during transfection, hence its name. This gene encodes a cell membrane receptor tyrosine kinase, and its abnormalities are a rare driver of many types of tumors. |
| Hazard Information | Back Directory | [Description]
RET-IN-1 is an oral and selective investigational drug in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. | [Mechanism of action]
Receptor tyrosine kinase RET (rearranged during transfection) inhibitor |
|
| Company Name: |
Twochem Co.Ltd
|
| Tel: |
021-021-58111628 15800915896 |
| Website: |
www.twochem.com |
|